# SUPPLEMENTAL WORK-SARS-COV-2

> **NIH NIH N01** · HUMANETICS CORPORATION · 2021 · $1,872,652

## Abstract

The company will initiate a phase 2 trial to evaluate BIO 300 (oral, genistein antioxidant) to mitigate impaired pulmonary function in COVID-19 patients recently discharged from the hospital. COVID-19- and radiation-mediated lung damage share overlapping mechanisms of injury, and Humanetics already has BIO300 under study in the clinic to treat pneumonitis and pulmonary fibrosis in lung cancer patients receiving thoracic radiotherapy.

## Key facts

- **NIH application ID:** 10397497
- **Project number:** 272201800011C-P00013-9999-2
- **Recipient organization:** HUMANETICS CORPORATION
- **Principal Investigator:** MICHAEL KAYTOR
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,872,652
- **Award type:** —
- **Project period:** 2019-04-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10397497

## Citation

> US National Institutes of Health, RePORTER application 10397497, SUPPLEMENTAL WORK-SARS-COV-2 (272201800011C-P00013-9999-2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10397497. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*